Therapeutic effect of atomized inhalation of Budesonide for chronic cough after Mycoplasma pneumoniae infection in children

Abstract

Objective To investigate the therapeutic effect of Budesonide inhalation for the children with chronic cough after Mycoplasma pneumoniae infection and its influence on the improvement of sleep quality. Methods One hundred children with chronic cough after Mycoplasma pneumoniae infection treated at Shanghai Tongji Hospital(Tongji Hospital Affiliated to Tongji University) were selected from June to December 2016, and they were randomly divided into the Budesonide group and the Azithromycin group.The Budesonide group received the Budesonide inhalation, the atomized inhalation 1 mg each time, 2 times a day, for 3 consecutive days, and 3 days later, they received ato-mization treatment once a day, for a total of 7 days.The patients in the Azithromycin group were given oral the Azithromycin treatment 10 mg/ (kg·d) for 3 days.The efficacy and sleep scores of 2 groups were compared during the period. Results The cure rate of cough in the Budesonide group[8.0%(4/50 cases), 32.0%(16/50 cases), 38.0%(19/50 cases)]was higher than those in the Azithromycin group[0(0/50 cases), 4.0%(2/50 cases), 6.0%(3/50 cases)]during 3, 7, 14 days, and the differences were all statistically significant (χ2= 4.167, 13.279, 14.918, all P<0.05). The improvement rates of cough in the Budesonide group[28.0%(14/50 cases), 28.0%(14/50 cases), 26.0%(13/50 cases)]were higher than those in the Azithromycin group[10.0%(5/50 cases), 10.0%(5/50 cases), 8.0%(4/50 cases)]in treatment 3, 7, 14 days, and the differences were all statistically significant (χ2= 5.263, 5.263, 5.741, all P<0.05). Nighttime sleep scores returned to normal ratio and improvement rates during 3, 7, 14 days in the Budesonide group [8.0%(4/50 cases), 32.0%(16/50 cases), 42.0%(21/50 cases); 30.0%(15/50 cases), 30.0%(15/50 cases), 30.0%(15/50 cases)], which were significantly higher than those in the Azithromycin group[0(0/50 cases), 4.0%(2/50 cases), 6.0%(3/50 cases); 12.0%(6/50 cases), 12.0%(6/50 cases), 10.0%(5/50 cases)], and the differences were all statistically significant (all P<0.05). Conclusions The inhalation of Budesonide can effectively treat chronic cough in children with Mycoplasma pneumoniae infection in children, and significantly improve the quality of sleep.Chronic cough after Mycoplasma pneumoniae infection may be related to airway hyperresponsiveness due to nonspecific inflammation.Inhaled corticosteroids should be selected rather than anti infective therapy. Key words: Budesonide; Chronic cough; Mycoplasma pneumoniae; Azithromycin; Sleep quality